As Per the Report, the Middle East & Africa Next Generation Antibody Therapeutics Market size is valued at USD 0.33 billion in 2023 and is expected to grow at a CAGR of 2.6% to reach USD 0.37 billion by 2028 during the forecast period 2023 to 2028. It captures 8% of the global market share.
Next generation antibody therapeutics have high efficiency and are safer. Rapid advancements in monoclonal antibodies technology are the reason for this. These advances have improved bifunctional properties, decreased functional size along with immunogenicity. Several medical conditions like cancer; autoimmune diseases, etc. are treated using these technologies because of its enhanced properties.
A rising number of cases of chronic diseases, rapid advancements in technology, higher investment in R&D and increasing healthcare expenditure are the primary drivers of market growth. On the other hand, strict administrative guidelines and regulatory requirements and inordinate delays in approval for new drugs along with their high costs are the primary restraints of market growth.
Middle East & Africa Next-Generation Antibody Therapeutics Market has been segmented and sub-segmented into the following categories
On the basis of region, MEA continues to be the least attractive market in the forecast period.
Key Market Companies dominating the Middle East & Africa Next Generation Antibody Therapeutics Market include Roche, Seattle Genetics, Takeda, Dyax Corp., and Immunogen, Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc., and Xencor, Inc.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1200
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region